Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins

Cancer Treatment Reviews

Volumn 40, Issue 1, 2014, Pages 93-101

  Remon, J ^a   Moran T ^b   Majem, M ^c   Reguart, N ^d   Dalmau, E ^e   Marquez Medina D ^f   Lianes, P ^a  

^a HOSPITAL DE MATARÓ   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f HOSPITAL ARNAU DE VILANOVA   (Spain)

Author keywords

Acquired resistance; EGFR mutant tumors; Non small cell lung cancer; Tyrosine kinase inhibitors

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; AFATINIB; AP 26113; BUPARLISIB; CABOZANTINIB; CETUXIMAB; CISPLATIN; CO 1686; CRIZOTINIB; DACOMITINIB; ENTINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; GOLVATINIB; JSI 124; LUMINESPIB; METHIONINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; ONARTUZUMAB; PIMASERTIB; PLATINUM; POZIOTINIB; SELUMETINIB; SMALL INTERFERING RNA; TIVANTINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; WZ 4002;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER REGRESSION; CANCER RESISTANCE; CHEMOSENSITIVITY; CLINICAL PRACTICE; DIARRHEA; DRUG ERUPTION; DRUG POTENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NONHUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT RESPONSE; WILD TYPE;

ACQUIRED RESISTANCE; EGFR-MUTANT TUMORS; NON-SMALL CELL LUNG CANCER; TYROSINE KINASE INHIBITORS;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84887111018     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.06.002     Document Type: Review

References (114)

1. Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
2. Yang J.-CH., Schuler M., Yamamoto N., et al. LUX-lung 3: a randomized open-label phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 2012, 30. (LBA 7500).
3. Sordella R., Bell D.W., Haber D.A., Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004 Aug 20, 305(5687):1163-1167.
4. Mitsudomi T., Morita S., Yatabe Y., et al. Gefitnib versus cisplatin plus docetaxel in patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol 2010, 11:121-183.
5. Zhou C., Wu Y.L., Chen G., et al. Erlotinib versus chemotherapy as first line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised phase 3 study. Lancer Oncol 2011, 12:735-742.
6. Rosell R., Carcereny E., Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicenter, open-label, randomized phase 3 trial. Lancet Oncol 2012, 13:239-246.
7. Inoue A., Kobayashi K., Maemondo M., et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR mutations (NEJ002). Ann Oncol 2013, 24:54-59.
8. Riely G.J., Kris M.G., Zhao B., et al. Prospective assessment of discontinuation and re-initiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
9. Kobayashi S., Boggon T.J., Dayaram, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352:786-792.
10. Engelman J.A., Mukohara T., Zenjullahu K., et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest 2006, 116:2695-2706.
11. Arcila M.E., Oxnard G.R., Nafa K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011, 17:1169-1180.
12. Yun C.H., Mengwasser K.E., Toms A.V., et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 2008, 105:2070-2075.
13. Rosell R., Molina M.A., Costa C., et al. Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011, 17:1160-1168.
14. Chmielecki J., Foo J., Oxnard G.R., et al. Optimizing of dosing for EGFR-mutant nonsmall cell lung cancer with evolutionary cancer modelling. Sci Transl Med 2011, 3. (90ra59).
15. Oxnard G.R., Arcila M.E., Sima C.S., et al. Acquired resistance to EGFR tyrosine kinase inhibitor in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
16. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005, 102:7665-7670.
17. Engelman J.A., Zejnullahu K., Gale C.M., et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007, 67:11924-11932.
18. Sequist L.V., Besse B., Lynch T.J., et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
19. Miller V.A., Hirsh V., Cadranel J., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012, 13:528-538.
20. Regales L., Gong Y., Shen R., et al. Dual targeting of EGFR can overcome a major drug resistance in mouse model of EGFR-mutant lung cancer. J Clin Invest 2009, 119:3000-3010.
21. Janjigian Y.Y., Smit E.F., Horn L., et al. Activity of afatinib/cetuximab in patients with EGFR-mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. ESMO 2012, (Abstract 12270).
22. Wang M., Zhao J., Zhang L.M., et al. Combined erlotinib and cetuximab overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in non-small-cell lung cancer. J Cancer Res Clin Oncol 2012, 138:2069-2077.
23. Janjigian Y.Y., Azzoli C.G., Krug L.M., et al. Phase I/II of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011, 17:2521-2527.
24. Zhou W., Ercan D., Chen L., et al. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 2009, 462:1070-1074.
25. Blakely C.M., Bivona T.G. Resiliency of lung cancer to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discovery 2012, 2:872-875.
26. Lee H.J., Schaefer G., Heffron T.P., et al. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discover 2013, 3:168-181.
27. Sequist I.V., Soria J.C., Gadgeel S.M., et al. First-in-human evaluation of co-1686 an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M. J Clin Oncol 2013, 31. (Abstract 2524).
28. Bean J., Riely G.J., Malak M., et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in patients with EGFR-mutant lung adenocarcinoma. Clin Cancer Res 2008, 22:7519-7525.
29. Costa D.B., Schumer S.T., Tenen D.G., Kobayashi S. Differential response to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-mutate lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutation. J Clin Oncol 2008, 26:1182-1184.
30. Balak M.N., Gong Y., Riely G.J., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor mutant lung adenocarcinoma with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12:6494.
31. Robinson K.W., Sandler A.B. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. The Oncologist 2013, 18:115-122.
32. Engelman J.A., Zejnullahu K., Mitsudomi T., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalling. Science 2007, 316:1039-1043.
33. Bean J., Brennan C., Shih J.Y., et al. MET amplification occurs with or without T790M mutation in EGFR-mutant lung cancer tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007, 104:20932-20937.
34. Sequist L.V., Waltman B.A., Dias Santagata D., et al. Genotyping and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75).
35. Oxnard G.R., Arcila M.E., Chmielecki J., et al. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17:5530-5537.
36. Suda K., Murakami I., Katayama T., et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010, 16:5489-5498.
37. Sequist L.V., von Pawel J., Garmey E.G., et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small cell lung cancer. J Clin Oncol 2011, 29:3307-3315.
38. Spigel D.R., Ervin T.J., Ramlau R., et al. Final efficacy results from OAM4558g a randomized phase II study evaluating MetMab or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011, (Abstract 7505).
39. Jänne P.A., Wax M., Leach J.W., et al. Targeting MET with XL184 to reverse EGFR tyrosine kinase inhibitor resistance in NSCLC: impact of preclinical studies on clinical trial design. Eur J Cancer Suppl 2008, 6:174.
40. Yano S., Wang W., Li Q., et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutation. Cancer Res 2008, 68:9479-9487.
41. Turke A.B., Zejnullahu K., Wu Y.L., et al. Pre-existence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
42. Yano S., Yamada T., Takeuchi S., et al. Hepatocyte growth factor expression in EGFR-mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac oncol 2011, 6:2011-2017.
43. Uramoto H., Yamada T., Yano S., et al. Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR TKI. Anticancer Res 2012, 32:3785-3790.
44. Sano T., Takeuchi S., Nakagawa T., et al. The novel phosphoinositide 3-Kinase-mammalina target of rapamycin inhibitor, BEZ235, circumvetes erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer 2013, 133:505-513.
45. Koizumi H., Yamada T., Takeuchi S., et al. HSP90 inhibition overcomes HGF-triggering resistnace to EGFR TKI in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol 2012, 7:1078-1085.
46. Felip E., Carcereny E., Barlesi F., et al. Phase II activity of the HSP90 inhibitor in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer. ESMO 2012, (Abstract 4380).
47. Johnson M.L., Hart M.E., Rademaker A., et al. A phase II of HSP90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer and acquired resistance to EGFR tyrosine kinase inhibitors. J Clin Oncol 2013, 31. (Abstract 8036).
48. Yu H.A., Arcila M.E., Rekhtman N., et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013, 19:2240-2247.
49. Nakagawa T., Takeuchi S., Yamada T., et al. Combined therapy with mutant-selective EGFR inhibitor and MET kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 2012, 11:2149-2157.
50. Meuwissen R., Lin S.C., Linnoila R.I., et al. Induction small cell lung cancer by somatic inactivation of both p53 and Rb1 in a conditional mouse model. Cancer Cell 2003, 4:181-189.
51. Uramoto H., Iwata T., Onitsuka T., et al. Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 2010, 30:2513-2517.
52. Coldren C.D., Helfrich B.A., Witta S.E., et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006, 4:521-528.
53. Yaunch R.L., Januario T., Eberhard D.A., et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
54. Suda K., Tomizawa K., Fujii M., et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011, 6:1152-1161.
55. Zhang X., Liu G., Kang Y., et al. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 2013, 8. (Epub ahead of print).
56. Xie M., Zhang L., He C.S., et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 2012, 113:1501-1513.
57. Serizawa M., Takahasi T., Yamamoto N., Koh Y. Combined treatment with erlotinib and a transforming growth factor β Type I receptor inhibitor effectively supress the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. J Thorac Oncol 2013, 8:259-269.
58. Shan B., Yao T.P., Nguyen H.T., et al. Requirement of HDAC6 for transforming growth factor-beta-1-induced epithelial-mesenchymal transition. J Biol Chem 2008, 283:21065-21073.
59. Witta S.E., Gemmill R.M., Hirsch F.R., et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006, 66:944-950.
60. Witta S.E., Jotte R.M., Konduri L. Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 2012, 30:2248-2255.
61. Morgillo F., Cascone T., D'Aiuto E., et al. Antitumor efficacy of MEK inhibitors in human lung cancer cells and their derivates with acquired resistance to different tyrosine kinase inhibitors. B J Cancer 2011, 105:382-392.
62. Zhang Z., Lee J.C., Lin L., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics 2012, 44:852-860.
63. Byers L.A., Diao L., Wang J., et al. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target overcoming EGFR inhibitor resistance. Clin Cancer Res 2013, 19:279-290.
64. Chaft J.E., Arcila M.E., Paik P.K., et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012, 11:485-491.
65. Endoh H., Yatabe Y., Kosaka T., et al. PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. J Thorac Oncol 2006, 1:629-634.
66. Gadgeel S.M., Wozniak A. Preclinical rational for PI3K/AKT/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin Lung Cancer 2013, 15. (Epub ahead of print).
67. Tan D.S.W., Lim K.H., Tai W.M., et al. A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib in EGFR TKI-resistant NSCLC. J Clin Oncol 2013, 31. (Abstract 8107).
68. Yamamoto C., Basaki Y., Kawahara A., et al. Loss of PTEN expression by blocking nuclear translocation of EGFR1 in gefitinib-resistant lung cancer cell harbouring epidermal growth factor receptor-activating mutations. Cancer Res 2010, 70:8715-8725.
69. Mendes-Pereira A.M., Martin S.A., Brough R., et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009, 1:315-322.
70. Takezawa K., Pirazzoli V., Arcila M.E., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibitor in EGFR-mutant lung cancers that lack the second-site EGFR T790M mutation. Cancer Discover 2012, 2:922-933.
71. Altavilla G., Arrigo C., Tomasello C.H., et al. Ocurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistance to EGFR-TKIS. J Clin Oncol 2013, 31. (Abstract 8047).
72. Ercan D., Xu C., Yanagita M., et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discover 2012, 2:934-947.
73. Huang M.H., Lee J.H., Chang Y.J., et al. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 2013, 7:112-120.
74. Ohashi K., Sequist L.V., Arcila M.E., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbour BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. PNAS 2012, 109:E2127-E2133.
75. Alvarez J.V., Greulich H., Sellers W.R., et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006 Mar 15, 66(6):3162-3168.
76. Song L., Rawal B., Nemeth J.H., Haura E.B. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can supress JAK1-STAT3 signalling. Mol Cancer Ther 2011, 10:481-494.
77. Harada D., Takigawa N., Ochi N., et al. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation. Cancer Sci 2012, 103:1795-1802.
78. Guix M., Faber A.C., Wang S.E., et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008, 118:2609-2619.
79. Cortot A.B., Repellin C.E., Shimamura T., et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through multistep mechanism involving the IGF1R pathway. Cancer Res 2013, 73:834-843.
80. Tabara K., Kanda R., Sonoda K., et al. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. PLoS One 2012, 7:e41017.
81. Shien K., Toyooka S., Yamamoto H., et al. Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells. Cancer Res 2013, 15:3051-3061.
82. Jackman D., Pao W., Riely G.J., et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Clin Oncol 2010, 28:357-360.
83. Johnson B.E., Kris M.G., Berry L.D., et al. A multicentre effort to identify driver mutation and employ targeted therapy in patients with lung adenocarcinomas The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2013, 31. (Abstract 8019).
84. Kuiper J.L., Heideman D., Thurnnisen E., et al. Rebiopsy in TKI-resistance: a retrospective analysis. J Clin Oncol 2013, 31. (Abstract 8065).
85. Murtaza M., Dawson S.J., Tsui D.W., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
86. Nakamura T., Sueoka-Aragane N., Iwanaga K., et al. A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 2011, 6:1639-1648.
87. Hirsch F.R., Jänne P.A., Eberhardt W.E. Epidermal growth factor receptor inhibition in lung cancer, Status. J Thoracic Oncol 2012, 2013(8):373-384.
88. Nishino M., Cardarella S., Dahlberg S.E., et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine-kinase inhibitors. Lung Cancer 2013, 79:283-288.
89. Asami K., Akuma T., Hirashima T., et al. Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations. Lung Cancer 2013, 79:276-282.
90. Oxnard G.R., Lo P., Jackman D.M., et al. Delay of chemotherapy through use of post-progression erlotinib in patients with EGFR-mutant lung cancer. J Clin Oncol 2012, 30. (Abstract 7547).
91. Yu H.A., Sima C.S., Huang J., et al. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have a developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol 2013, 8:346-351.
92. Weickhardt A.J., Scheier B., Burke J.M., et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR-mutant and ALK+small cell lung cancer. J Clin Oncol 2012, 30. (Abstract 7526).
93. Watanabe S., Tanaka J., Ota T., et al. Clinical response to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: A retrospective analysis. BMC Cancer 2011, 11:1.
94. Heon S., Nishino M., Goldberg S., et al. Response to EGFR tyrosine kinase inhibitor retreatment after a drug-free interval in EGFR-mutant advanced non-small cell lung cancer with acquired resistance. J Clin Oncol 2012, 30(Suppl.). (Abstract 7525).
95. Kaira K., Naito T., Takahashi T., et al. Pooled analysis of the reports of erlotinib after failure if gefitinib for non-small cell lung cancer. Lung cancer 2010, 68:99-104.
96. Hata A., Katakami N., Yoshioka H., et al. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selection. Lung cancer 2011, 74:268-273.
97. Wu J.Y., Shih J.Y. Yang CH t al. Second-line treatments after first-line gefitinib therapy in advanced non-small cell lung cancer. Int J Cancer 2010, 126:247-255.
98. Gridelli C., Ciardiello F., Gallo C., et al. First-line erlotinib followed by second-line cisplatin-gemcitabine in advanced non-small cell lung cancer: The TORCH randomized trial. J Clin Oncol 2012, 20:3002-3011.
99. Chaft J.E., Oxnard G.R., Sima C.S., et al. Disease flare after tyrosine kinase discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
100. Goldberg S.B., Oxnard G.R., Digumarthy S., et al. Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC and acquired resistance to EGFR tyrosine kinase inhibitors. J Clin Oncol 2012, 30. (Abstract 7524).
101. Faehling M., Eckert R., Kamp T., et al. EGFR tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: A case-control study of overall survival. Lung cancer 2013, 80:306-312.
102. Halmos B., Pennell N.A., Otterson G.A., et al. Erlotinib beyond progression study randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor-responsive non-small cell lung cancer that subsequently progresses. J Clin Oncol 2013, 31. (Abstract 8114).
103. Shimizu T., Nakanishi Y., Nakagawa Y., et al. Association between expression of thymidylate synthase, dihidrofolate reductase and glycinamide ribonucleotide formyltransferase and efficacy of pemetrexed in advanced non-small cell lung cancer. Anticancer Res 2012, 32:4589-4596.
104. Okabe T., Okamoto I., Tsukioka S., et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009, 15:907-913.
105. Yoshimura N., Okishio K., Mitsuoka S., et al. Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed. J Thorac Oncol 2013, 8:96-101.
106. Omuro A.M., Kris M.G., Miller V.A., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with non-small cell lung carcinoma after response to gefitinib. Cancer 2005, 103:2344-2348.
107. Sekine A., Kato T., Hagiwara E., et al. Metastatic brain tumors from non-small cell lung cancer with EGFR mutation: distinguishing influence of exon 19 deletion or radiographic features. Lung cancer 2012, 77:64-69.
108. Hata A., Ktakami N., Yoshioka H., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI Comparison between T790M mutation-positive nad -negative populations. J Clin Oncol 2012, (Suppl.):487s. (Abstract 7528).
109. Grommes C., Oxnard G.R., Kris M.G., et al. Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13:1364-1369.
110. Zhao J., Chen M., Zhong W., et al. Cerebroespinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cacner 2013, 14:188-193.
111. Hirata H., Nakamura K., Kunitake N., et al. Association between EGFR-TKI resistance and efficacy of radiotherapy for brain metastases from EGFR-mutant lung adenocarcinoma. Anticancer Res 2013, 33:1649-1655.
112. Togashi Y., Masago K., Fukudo M., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011, 68:1089.
113. Kawamura T., Hata A., Otoshi T., et al. High-dose erlotinib for refractory leptomeningeal metastases after failure of standard dose EGFR-TKIs. J Clin Oncol 2013, 31. (Abstract 8098).
114. Yang J.J., Chen H.J., Yan H.H., et al. Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung cancer 2013, 79:33-39.